Kamada Announces Special Cash Dividend
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a prominent biopharmaceutical company, recently declared a special cash dividend of $0.20 per share. This significant announcement follows a exceptional financial performance for the company, firmly positioning it as a leader in the specialty plasma-derived therapies sector. The dividend, totaling approximately $11.5 million, aims to reward shareholders and marks the first special cash dividend in the company's history.
CEO's Statement on the Dividend
Amir London, the CEO of Kamada, expressed excitement about the dividend declaration. He linked this decision to the company's robust financial results and favorable cash position, indicating the organization’s commitment to shareholder value. London emphasized that the company is well-equipped for continued growth, primarily through various initiatives such as organic expansion, strategic business development, and enhancing plasma collection operations.
Strategic Growth Pillars
The company's growth strategy revolves around four key pillars. First, Kamada focuses on organic growth from commercial activities, aimed at maximizing the potential of its proprietary products. This includes several FDA-approved specialty products like KEDRAB®, CYTOGAM®, and GLASSIA®, among others. Each of these products plays a crucial role in addressing the significant medical needs in various healthcare settings.
Business Development Initiatives
In addition to nurturing existing products, Kamada seeks to bolster its portfolio through new business development. This may involve in-licensing, forming collaborations, or pursuing mergers and acquisitions, all designed to enhance the company's capabilities. Such strategies not only broaden the product offerings but also capitalize on Kamada's solid financial standing and operational infrastructure.
Expansion of Plasma Collection
To facilitate revenue growth, Kamada is also expanding its plasma collection operations. Currently, the company operates two centers in Texas, with plans for a third in San Antonio. This expansion will not only increase the supply of normal source plasma but also support the growing demand for specialized hyper-immune plasma, ensuring the company can meet its operational and product development requirements effectively.
Innovative Product Development
One of the standout initiatives of Kamada is the lead product candidate, Inhaled AAT. The company is actively progressing through clinical trials to validate this promising treatment, aiming to fill the significant gaps in respiratory care. As such trials continue, there is ample opportunity for success in introducing new therapies that address critical health challenges.
Tax Implications of the Dividend
As with any dividend declaration, shareholders should be aware of the tax implications. Kamada plans to withhold taxes on the dividend per Israeli tax law. The company is currently securing a ruling from the Israel Tax Authority regarding tax responsibilities for non-Israeli shareholders, and updates will follow upon receipt of that ruling.
Conclusion
Kamada’s special cash dividend announcement signals a pivotal moment for the company and its shareholders. As it builds on a foundation of robust financial results and a strategic focus on growth, Kamada continues to provide valuable returns to its investors. This commitment not only highlights the organization’s solid performance but also strengthens the relationship with its shareholder base, reinforcing trust and involvement in the company’s vision moving forward.
Frequently Asked Questions
What is the amount of the special cash dividend announced by Kamada?
The company has declared a special cash dividend of $0.20 per share.
When will the special dividend be paid out?
The special cash dividend is set to be payable on a specified date in April to shareholders of record prior to that date.
Why did Kamada decide to issue a special cash dividend?
The decision was influenced by the company’s strong financial performance and confidence in its growth prospects.
What are the growth pillars of Kamada Ltd.?
Kamada's growth strategy focuses on organic growth, business development opportunities, expanding plasma collection operations, and advancing innovative product candidates.
Is there a tax withholding on the dividend for shareholders?
Yes, the company will withhold taxes on the dividend as per Israeli law and will provide further details regarding non-Israeli shareholders in due course.
